var docs;if (!docs) docs =[]; docs["108"]={"10800":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased neuromuscular blocking agent effectiveness if used in combination with carbamazepine. Increased doses of the neuromuscular-blocking agent may be required.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> In 2 pharmacokinetic studies, vecuronium clearance was 2.1-fold to 2.5-fold higher in patients receiving chronic carbamazepine therapy compared with that of patients not receiving carbamazepine therapy.<sup>1,2</sup> Numerous studies have demonstrated that patients on carbamazepine therapy have higher dose requirements and/or faster recovery times compared with control patients when treated with vecuronium,<sup>1,2,3,4</sup> pancuronium,<sup>5</sup> rocuronium,<sup>6,7,8,9</sup> cisatricurium,<sup>10,11</sup> and atracurium.<sup>12</sup> Cases of carbamazepine treated patients requiring higher than expected doses of vecuronium, rocuronium, and rapacuronium have also been reported.<sup>13,14,15</sup><br><br>In contrast, 2 studies describe no difference in the time to recovery between carbamazepine treated patients and controls with the use of atracurium and mivacurium.<sup>16,17</sup><br><br>The mechanism of these interactions has not been fully investigated, but carbamazepine induction of enzymes responsible for the metabolism of neuromuscular-blocking agents is likely responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Soriano SG, Sullivan LJ, Venkatakrishnan K, Greenblatt DJ, Martyn JA. Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. <i>Br J Anaesth</i>. 2001;86(2):223-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11573664\">[PubMed 11573664]</a></p>\n<p>2. Alloul K, Whalley DG, Shutway F, Ebrahim Z, Varin F. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. <i>Anesthesiology</i>. 1996;84(2):330-339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8602663\">[PubMed 8602663]</a></p>\n<p>3. Whalley DG, Ebrahim Z. Influence of carbamazepine on the dose-response relationship of vecuronium. <i>Br J Anaesth</i>. 1994;72(1):125-126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7906533\">[PubMed 7906533]</a></p>\n<p>4. Hans P, Brichant JF, Pieron F, Pieyns P, Born JD, Lamy M. Elevated plasma alpha 1-acid glycoprotein levels: lack of connection to resistance to vecuronium blockade induced by anticonvulsant therapy. <i>J Neurosurg Anesthesiol</i>. 1997;9(1):3-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9016432\">[PubMed 9016432]</a></p>\n<p>5. Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. <i>Anesthesiology</i>. 1987;66(5):691-693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3578885\">[PubMed 3578885]</a></p>\n<p>6. Kawamura G, Inoue R, Araki Y, et al. Effects of preoperatively administered carbamazepine and phenytoin on rocuronium-induced neuromuscular block under sevoflurane anesthesia: a retrospective clinical study. <i>Masui</i>. 2014;63(8):877-880. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25199321\">[PubMed 25199321]</a></p>\n<p>7. Soriano SG, Kaus SJ, Sullivan LJ, Martyn JA. Onset and duration of action of rocuronium in children receiving chronic anticonvulsant therapy. <i>Paediatr Anaesth</i>. 2000;10(2):133-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10736074\">[PubMed 10736074]</a></p>\n<p>8. Koenig HM, Hoffman WE. The effect of anticonvulsant therapy on two doses of rocuronium-induced neuromuscular blockade. <i>J Neurosurg Anesthesiol</i>. 1999;11(2):86-89. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10213434\">[PubMed 10213434]</a></p>\n<p>9. Spacek A, Neiger FX, Krenn CG, Hoerauf K, Kress HG. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. <i>Anesthesiology</i>. 1999;90(1):109-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9915319\">[PubMed 9915319]</a></p>\n<p>10. Richard A, Girard F, Girard DC, et al. Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. <i>Anesth Analg</i>. 2005;100(2):538-544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673889\">[PubMed 15673889]</a></p>\n<p>11. Koenig MH, Edwards LT. Cisatracurium-induced neuromuscular blockade in anticonvulsant treated neurosurgical patients. <i>J Neurosurg Anesthesiol</i>. 2000;12(4):314-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11147379\">[PubMed 11147379]</a></p>\n<p>12. Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL. Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. <i>Anesth Analg</i>. 1990;71(6):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2240640\">[PubMed 2240640]</a></p>\n<p>13. Norman J. Resistance to vecuronium. <i>Anaesthesia</i>. 1993;48(12):1068-1069. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7904430\">[PubMed 7904430]</a></p>\n<p>14. Baraka A, Idriss N. Resistance to rocuronium in an epileptic patient on long-term carbamazepine therapy-a case report. <i>Middle East J Anaesthesiol</i>. 1996;13(6):561-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8987034\">[PubMed 8987034]</a></p>\n<p>15. Tobias JD, Johnson JO. Rapacuronium administration to patients receiving phenytoin or carbamazepine. <i>J Neurosurg Anesthesiol</i>. 2001;13(3):240-242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11426100\">[PubMed 11426100]</a></p>\n<p>16. Spacek A, Neiger FX, Spiss CK, Kress HG. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine. <i>Acta Anaesthesiol Scand</i>. 1997;41(10):1308-1311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9422297\">[PubMed 9422297]</a></p>\n<p>17. Spacek A, Neiger FX, Spiss CK, Kress HG. Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular block. <i>Br J Anaesth</i>. 1996;77(4):500-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8942336\">[PubMed 8942336]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10801":"<p><b>Title</b> Droxidopa / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of droxidopa and monoamine oxidase (MAO) inhibitors.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Syrian Rue, Tedizolid, Tranylcypromine<br><b>Exceptions</b> Rasagiline, Safinamide, Selegiline</p>\n</div> \n<p><b>Discussion</b> Droxidopa prescribing information states that although the concomitant use of selective MAO-B inhibitors (ie, rasagiline or selegiline) was permitted in the droxidopa clinical trials, based on the mechanism of action of droxidopa, the use of non-selective MAO inhibitors should be avoided due to a potential for increased blood pressure with the combination.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Northera (droxidopa) [prescribing information]. Deerfield, IL: Lundbeck NA Ltd; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10802":"<p><b>Title</b> Tacrolimus (Systemic) / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased tacrolimus serum concentrations and effects if combined with isavuconazonium. Tacrolimus dose reductions may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 20 healthy volunteers, isavuconazole (200 mg three times daily x 2 days, followed by 200 mg daily x 11 days) increased the tacrolimus (5 mg single dose) AUC and maximum serum concentration 125% and 42%, respectively.<sup>1</sup> <br><br>The mechanism of this interaction is likely due to isavuconazole inhibition of CYP3A4, an enzyme involved in tacrolimus metabolism. Inhibition of P-glycoprotein may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273343\">[PubMed 27273343]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10803":"<p><b>Title</b> Sirolimus / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased sirolimus serum concentrations and effects if combined with isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy volunteers, isavuconazole (200 mg three times daily x 2 days, followed by 200 mg daily x 11 days) increased the sirolimus (2 mg single dose) AUC and maximum serum concentration 84% and 65%, respectively.<sup>1</sup> <br><br>The mechanism of this interaction is likely due to isavuconazole inhibition of CYP3A4, an enzyme involved in sirolimus metabolism. Inhibition of P-glycoprotein may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273343\">[PubMed 27273343]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10804":"<p><b>Title</b> CycloSPORINE (Systemic) / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased cyclosporine concentrations and effects if combined with isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 19 healthy volunteers, isavuconazole (200 mg three times daily x 2 days, followed by 200 mg daily x 6 days) increased the cyclosporine (300 mg single dose) AUC and maximum serum concentration 29% and 6%, respectively.<sup>1</sup> <br><br>The mechanism of this interaction is likely due to isavuconazole inhibition of CYP3A4, an enzyme involved in cyclosporine metabolism. Inhibition of P-glycoprotein may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273343\">[PubMed 27273343]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10805":"<p><b>Title</b> Saquinavir / Antipsychotic Agents (Phenothiazines)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antipsychotic Agents (Phenothiazines) may enhance the arrhythmogenic effect of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Saquinavir use in combination with phenothiazines is listed as contraindicated in US product labeling due to a potential for serious reactions including cardiac arrhythmias.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> Saquinavir US labeling states that use with certain antipsychotic agents and classes, including clozapine, haloperidol, pimozide, ziprasidone, and phenothiazines, is contraindicated due to the potential for serious reactions including cardiac arrhythmias.<sup>1</sup> While no specific clinical data characterize a potential interaction between saquinavir and these agents or classes, they all (including saquinavir) have been associated with QT interval lengthening and associated arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10806":"<p><b>Title</b> Saquinavir / CloZAPine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CloZAPine may enhance the arrhythmogenic effect of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Saquinavir use in combination with clozapine is listed as contraindicated per US product labeling due to a potential for serious reactions including cardiac arrhythmias.</p> \n<p><b>Discussion</b> Saquinavir US labeling states that use with certain antipsychotic agents and classes, including clozapine, haloperidol, pimozide, ziprasidone, and phenothiazines, is contraindicated due to the potential for serious reactions including cardiac arrhythmias.<sup>1</sup> While no specific clinical data characterize a potential interaction between saquinavir and these agents or classes, they all (including saquinavir) have been associated with QT interval lengthening and associated arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10807":"<p><b>Title</b> Saquinavir / Haloperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Haloperidol may enhance the arrhythmogenic effect of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Saquinavir use in combination with haloperidol is listed as contraindicated in US product labeling due to a potential for serious reactions including cardiac arrhythmias.</p> \n<p><b>Discussion</b> Saquinavir US labeling states that use with certain antipsychotic agents and classes, including clozapine, haloperidol, pimozide, ziprasidone, and phenothiazines, is contraindicated due to the potential for serious reactions including cardiac arrhythmias.<sup>1</sup> While no specific clinical data characterize a potential interaction between saquinavir and these agents or classes, they all (including saquinavir) have been associated with QT interval lengthening and associated arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10808":"<p><b>Title</b> Saquinavir / Pimozide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pimozide may enhance the arrhythmogenic effect of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Saquinavir use in combination with pimozide is listed as contraindicated in US product labeling due to a potential for serious reactions including cardiac arrhythmias.</p> \n<p><b>Discussion</b> Saquinavir US labeling states that use with certain antipsychotic agents and classes, including clozapine, haloperidol, pimozide, ziprasidone, and phenothiazines, is contraindicated due to the potential for serious reactions including cardiac arrhythmias.<sup>1</sup> While no specific clinical data characterize a potential interaction between saquinavir and these agents or classes, they all (including saquinavir) have been associated with QT interval lengthening and associated arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10809":"<p><b>Title</b> Saquinavir / Ziprasidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ziprasidone may enhance the arrhythmogenic effect of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Saquinavir use in combination with ziprasidone is listed as contraindicated in US product labeling due to a potential for serious reactions including cardiac arrhythmias.</p> \n<p><b>Discussion</b> Saquinavir US labeling states that use with certain antipsychotic agents and classes, including clozapine, haloperidol, pimozide, ziprasidone, and phenothiazines, is contraindicated due to the potential for serious reactions including cardiac arrhythmias.<sup>1</sup> While no specific clinical data characterize a potential interaction between saquinavir and these agents or classes, they all (including saquinavir) have been associated with QT interval lengthening and associated arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10810":"<p><b>Title</b> Rosuvastatin / Telmisartan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Telmisartan may increase the serum concentration of Rosuvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In clinical studies of healthy volunteers, coadministration of telmisartan (80 mg daily, with or without coformulated amlodipine 10 mg daily) increased the maximum concentration (Cmax) and AUC of rosuvastatin (20 mg/day) by 2.0- to 2.1-fold and 13% to 26%, respectively.<sup>1,2</sup> The mean telmisartan AUC increased by 17% to 30% with rosuvastatin coadministration in these studies, while Cmax increased by 35% in one study but was unchanged in the other. Similarly, in smaller studies of healthy volunteers (n=7) and patients with hyperlipidemia (n=9), coadministration of telmisartan (40 mg daily) and rosuvastatin (10 mg single dose or 10 mg daily) increased rosuvastatin Cmax by 68% to 75% without affecting rosuvastatin AUC or telmisartan Cmax or AUC.<sup>3</sup><br><br>A published case report describes a 66 year old woman receiving telmisartan, warfarin, ranitidine, furosemide, and carvedilol who developed rhabdomyolysis 5 months after rosuvastatin (10 mg/day) initiation.<sup>4</sup> Evidence of muscular toxicity disappeared shortly after rosuvastatin discontinuation, and reemerged only 2 days after starting a second course of rosuvastatin. The patient later tolerated pravastatin (40 mg daily) in place of rosuvastatin. Any role telmisartan may have had in promoting rosuvastatin toxicity in this case is unclear.<br><br>The mechanism of this interaction is unclear. Telmisartan inhibition of ABCG2- (also known as BCRP) mediated rosuvastatin efflux may contribute.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Son M, Kim Y, Lee D, et al. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. <i>Clin Ther</i>. 2014;36(8):1147-1158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24998012\">[PubMed 24998012]</a></p>\n<p>2. Son M, Guk J, Kim Y, et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: A randomized, open-label, multiple-dose, 2-period crossover study. <i>Clin Ther</i>. 2016;38(8):1845-1857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27422590\">[PubMed 27422590]</a></p>\n<p>3. Hu M, Lee HK, To KK, et al. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin [published online September 20, 2016]. <i>Eur J Clin Pharmaco.</i>. doi: 10.1007/s00228-016-2130-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27651239\">[PubMed 27651239]</a></p>\n<p>4. Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De Sarro G. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. <i>Drug Metabol Drug Interact</i>. 2009;24(1):83-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19354002\">[PubMed 19354002]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10811":"<p><b>Title</b> Didanosine / Ganciclovir-Valganciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving ganciclovir or valganciclovir with didanosine closely for evidence of didanosine toxicity. Didanosine US product labeling notes that appropriate doses for this combination have not been established.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n</div> \n<p><b>Discussion</b> The AUC of didanosine was increased by 50% to 115% in several studies of concomitant therapy with intravenous or oral ganciclovir.<sup>1,2,3</sup> Ganciclovir exposure in these studies was unaffected.<sup>1,2</sup><br><br>The mechanism of this interaction is unclear. It does not appear to involve alterations in didanosine renal clearance.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>. 1998;17(3):227-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9495222\">[PubMed 9495222]</a></p>\n<p>2. Valcyte (valganciclovir) [prescribing information]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; July 2014.</p>\n<p>3. Griffy KG. Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. <i>AIDS</i>. 1996;10(Suppl 4):S3-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9110063\">[PubMed 9110063]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10812":"<p><b>Title</b> Zidovudine / Ganciclovir-Valganciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving ganciclovir or valganciclovir with zidovudine closely for evidence of hematologic toxicity.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n</div> \n<p><b>Discussion</b> In a study of 40 patients, severe or life-threatening hematologic toxicity was present in 82% of patients treated with zidovudine (600-1200 mg/day) and ganciclovir (5 mg/kg twice daily for 14 days, then 5 mg/kg/day 5 days weekly).<sup>1</sup> Lowering the dose of zidovudine slightly lessened the incidence of severe toxicity, but efficacy was not improved. Similarly, among patients treated with combination zidovudine and ganciclovir, 6/7 experienced hematologic toxicity as compared to only 1/9 patients treated with ganciclovir alone.<sup>2</sup> A case report also describes prolonged pancytopenia during concomitant therapy with these agents.<sup>3</sup><br><br>The mechanism of this interaction is unclear, although in vitro studies suggest that these drugs exert synergistic cytotoxic effects.<sup>4</sup> Coadministration in a clinical study had no impact on ganciclovir and zidovudine pharmacokinetics.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. <i>Ann Intern Med</i>. 1990;113(2):111-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2163228\">[PubMed 2163228]</a></p>\n<p>2. Millar AB, Miller RF, Patou G, Mindel A, Marsh R, Semple SJ. Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. <i>Genitourin Med</i>. 1990;66(3):156-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2164492\">[PubMed 2164492]</a></p>\n<p>3. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. <i>J Infect Dis</i>. 1988;158(2):489-490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3261316\">[PubMed 3261316]</a></p>\n<p>4. Prichard MN, Prichard LE, Baguley WA, Nassiri MR, Shipman C Jr. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. <i>Antimicrob Agents Chemother</i>. 1991;35(6):1060-1065. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1929243\">[PubMed 1929243]</a></p>\n<p>5. Valcyte (valganciclovir) [prescribing information]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10813":"<p><b>Title</b> Sympathomimetics / Cocaine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cocaine (Topical) may enhance the hypertensive effect of Sympathomimetics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.</p>\n<div>\n <p><b>Sympathomimetics Interacting Members</b> Acebrophylline, Albuterol, Amezinium, Aminophylline, Amphetamine, Arformoterol, Armodafinil, Bambuterol, Benzphetamine, Bitter Orange, Caffeine, Cocaine (Topical), Dexmethylphenidate, Dextroamphetamine, Diethylpropion, DOBUTamine, DOPamine, Doxapram, Dyphylline, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Fenoterol, Formoterol, Indacaterol, Isometheptene, Isoproterenol, Kola Nut, Levalbuterol, Levonordefrin, Lisdexamfetamine, Metaproterenol, Metaraminol, Methamphetamine, Methylphenidate, Midodrine, Modafinil, Naphazoline (Nasal), Naphazoline (Ophthalmic), Norepinephrine, Olodaterol, Oxymetazoline (Nasal), Phendimetrazine, Phentermine, Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Pirbuterol, Propylhexedrine, Pseudoephedrine, Ritodrine, Salmeterol, Terbutaline, Theophylline, Tulobuterol, Vilanterol, Xylometazoline</p>\n</div> \n<p><b>Discussion</b> Several case reports describe patients who experienced myocardial ischemia, significant increases in blood pressure and heart rate, or ventricular fibrillation following topical or local administration of cocaine together with a vasoconstrictor.<sup>1,2,3,4,5,6,7,8</sup> These reports have involved the specific vasoconstrictors epinephrine<sup>1,2,3,4,5,6</sup> and phenylephrine.<sup>7,8</sup> Routes of administration have included topical intranasal, dermal, lacrimal, and subconjunctival.<br><br>The likely mechanism for this apparent interaction is enhancement of the sympathomimetic effects of drugs like epinephrine and phenylephrine via the catecholamine reuptake inhibiting and sympathomimetic potentiating effects of cocaine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McGovern E, Moylett E, McMahon CJ. Myocardial ischaemia following cocaine and adrenaline exposure in a child during an ophthalmological procedure. <i>Ir Med J</i>. 2015;108(3):89-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25876303\">[PubMed 25876303]</a></p>\n<p>2. Sundboll J, Pareek M, Hogsbro M, Madsen EH. Iatrogenic takotsubo cardiomyopathy induced by locally applied epinephrine and cocaine. <i>BMJ Case Rep</i>. 2014;2014 pii: bcr2013202401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24554679\">[PubMed 24554679]</a></p>\n<p>3. Laffey JG, Neligan P, Ormonde G. Prolonged perioperative myocardial ischemia in a young male: due to topical intranasal cocaine? <i>J Clin Anesth</i>. 1999;11(5):419-424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10526815\">[PubMed 10526815]</a></p>\n<p>4. Barnett P. Cocaine toxicity following dermal application of adrenaline-cocaine preparation. <i>Pediatr Emerg Care</i>. 1998;14(4):280-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9733253\">[PubMed 9733253]</a></p>\n<p>5. Nicholson KE, Rogers JE. Cocaine and adrenaline paste: a fatal combination? <i>BMJ</i>. 1995;311(6999):250-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7627047\">[PubMed 7627047]</a></p>\n<p>6. Lormans P, Gaumann D, Schwieger I, Tassonyi E. Ventricular fibrillation following local application of cocaine and epinephrine for nasal surgery. <i>ORL J Otorhinolaryngol Relat Spec</i>. 1992;54(3):160-162. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1518666\">[PubMed 1518666]</a></p>\n<p>7. Ashchi M, Wiedemann HP, James KB. Cardiac complication from use of cocaine and phenylephrine in nasal septoplasty. <i>Arch Otolaryngol Head Neck Surg</i>. 1995;121(6):681-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7772323\">[PubMed 7772323]</a></p>\n<p>8. Miller SA, Mieler WF. Systemic reaction to subconjunctival phenylephrine. <i>Can J Ophthalmol</i>. 1978;13(4):290-293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=743613\">[PubMed 743613]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10814":"<p><b>Title</b> Lapatinib / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US labeling describes this interaction as not clinically meaningful, but some non-US labels say this combination should be avoided.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Lapatinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> According to the UK lapatinib labeling, lapatinib exposure was an average of 27% lower (range 6% to 49%) following pretreatment with the proton pump inhibitor esomeprazole.<sup>1</sup> The UK labeling recommends that combined use of lapatinib with drugs that increase gastric pH should be avoided;<sup>1</sup> however, US lapatinib labeling states that the impact of esomeprazole (40 mg/day for 7 days) on lapatinib exposure was not clinically relevant, resulting in no such labeled warning.<sup>2</sup><br><br>Lapatinib does have reduced aqueous solubility at increased pH, which could result in decreased absorption and lower systemic concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015.</p>\n<p>2. Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10815":"<p><b>Title</b> Lapatinib / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US labeling describes this interaction as not clinically meaningful, but some non-US labels say this combination should be avoided.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Lapatinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> According to the UK lapatinib labeling, lapatinib exposure was an average of 27% lower (range 6% to 49%) following pretreatment with the proton pump inhibitor esomeprazole.<sup>1</sup> The UK labeling recommends that combined use of lapatinib with drugs that increase gastric pH should be avoided;<sup>1</sup> however, US lapatinib labeling states that the impact of esomeprazole (40 mg/day for 7 days) on lapatinib exposure was not clinically relevant, resulting in no such labeled warning.<sup>2</sup><br><br>Lapatinib does have reduced aqueous solubility at increased pH, which could result in decreased absorption and lower systemic concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015.</p>\n<p>2. Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10816":"<p><b>Title</b> Lapatinib / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US labeling describes this interaction as not clinically meaningful, but some non-US labels say this combination should be avoided.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Lapatinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> According to the UK lapatinib labeling, lapatinib exposure was an average of 27% lower (range 6% to 49%) following pretreatment with the proton pump inhibitor esomeprazole.<sup>1</sup> The UK labeling recommends that combined use of lapatinib with drugs that increase gastric pH should be avoided;<sup>1</sup> however, US lapatinib labeling states that the impact of esomeprazole (40 mg/day for 7 days) on lapatinib exposure was not clinically relevant, resulting in no such labeled warning.<sup>2</sup><br><br>Lapatinib does have reduced aqueous solubility at increased pH, which could result in decreased absorption and lower systemic concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015.</p>\n<p>2. Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10835":"<p><b>Title</b> Morphine (Systemic) / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Morphine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of morphine if rifampin is initiated/dose increased, or increased effects if rifampin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, the AUC and maximum serum concentration of morphine (10 mg daily) decreased by 28% and 41%, respectively, when coadministered with rifampin (600 mg daily), leading to complete loss of the analgesic effects of morphine.<sup>1</sup><br> <br>A case report describes a 51-year-old male who experienced inadequate analgesia and lower than expected serum morphine concentrations (19 ng/mL; expected level 67.93 ng/mL to 98.13 ng/mL) with the combination of morphine (morphine sustained release 75 mg three times daily) and rifampin (600 mg daily).<sup>2</sup> <br><br>The mechanism of interaction is unclear, but rifampin-mediated induction of UGT1A1,<sup>3</sup> UGT2B7,<sup>4</sup> and/or PGP,<sup>2</sup> may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fromm MF, Eckhardt K, Li S, et al, Loss of analgesic effect of morphine due to coadministration of rifampin. <i>Pain</i>. 1997;72(1-2):261-267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9272811\">[PubMed 9272811]</a></p>\n<p>2. Fudin I, Fontenelle DV, Payne A. Rifampin reduces oral morphine absorption: a case of transdermal buprenorphine selection based on morphine pharmacokinetics. <i>J Pain Palliat Care Pharmacother</i>. 2012;26(4): 362-367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23216174\">[PubMed 23216174]</a></p>\n<p>3. Vourvahis M, Davis J, Wang R, et al. Effect of rifampicin and rifabutin on the pharmacokinetics of lersivirine and the effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4303-4309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22644026\">[PubMed 22644026]</a></p>\n<p>4. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. <i>J Pharmacol Exp Ther</i>. 2001;299(3):849-857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11714868\">[PubMed 11714868]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10836":"<p><b>Title</b> NIFEdipine / Quinupristin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Quinupristin may increase the serum concentration of NIFEdipine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to quinupristin/dalfopristin prescribing information, administration of quinupristin/dalfopristin increased maximum concentration and AUC of nifedipine by 18% and 44%, respectively.<sup>1</sup> The likely mechanism of interaction between these agents is quinupristin/dalfopristin inhibition of CYP3A4 mediated nifedipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Synercid (quinupristin/dalfopristin) [prescribing information]. Greenville, NC: DSM Pharmaceuticals Inc; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10837":"<p><b>Title</b> Cannabidiol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use cannabidiol (CBD) in combination with strong CYP3A4 inhibitors closely for increased systemic CBD effects (eg, cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 5 days) and 4 sprays of the tetrahydrocannabinol and cannabidiol (CBD) oromucosal spray increased the maximum concentration (Cmax) and AUC of CBD by 1.9-fold and 1.8 fold, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of CBD.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. <i>Springerplus</i>. 2013;2(1):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23750331\">[PubMed 23750331]</a></p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10838":"<p><b>Title</b> Meptazinol / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Meptazinol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of meptazinol and ritonavir.</p> \n<p><b>Discussion</b> Meptazinol product labeling states that concomitant use of meptazinol and ritonavir should be avoided because ritonavir may increase meptazinol serum concentrations.<sup>1</sup> <br><br>The mechanism of this potential interaction is unknown. Although ritonavir is a known inhibitor of CYP3A4 and P-glycoprotein, the enzymes and transporters responsible for meptazinol metabolism and distribution have not been identified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meptid (meptazinol) [summary of product characteristics]. Middlesex, UK: Almirall Limited; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10839":"<p><b>Title</b> Ciprofloxacin (Systemic) / Meptazinol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Meptazinol may decrease the serum concentration of Ciprofloxacin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of meptazinol and ciprofloxacin.</p> \n<p><b>Discussion</b> Meptazinol product labeling states that concomitant use of meptazinol and ciprofloxacin should be avoided because meptazinol may decrease ciprofloxacin serum concentrations.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meptid (meptazinol) [summary of product characteristics]. Middlesex, UK: Almirall Limited; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10840":"<p><b>Title</b> Meptazinol / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Meptazinol product labeling states that the use of metptazinol with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) is contraindicated due to the potential for CNS excitation/depression, hypotension, or hypertension.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Meptazinol product labeling states that the use of metptazinol with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) is contraindicated due to the potential for CNS excitation/depression, hypotension, or hypertension.<sup>1</sup><br><br>The specific mechanism for this potential interaction is unclear. Whether this warning is simply related to the potential for each agent to independently alter CNS activity and/or blood pressure, or whether this relates to concerns over a theoretical potential for excessive serotonin stimulation is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meptid (meptazinol) [summary of product characteristics]. Middlesex, UK: Almirall Limited; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10841":"<p><b>Title</b> Gastrointestinal Agents (Prokinetic) / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effectiveness of prokinetic agents when combined with opioid analgesics.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n <p><b>Gastrointestinal Agents (Prokinetic) Interacting Members</b> Bromopride, Cisapride, Metoclopramide, Mosapride</p>\n</div> \n<p><b>Discussion</b> Product labeling for metoclopramide states that the prokinetic effects of metoclopramide on gastrointestinal motility may be antagonized by opioid analgesics.<sup>1,2,3</sup> These agents exert opposing effects on gastric motility, thus intended prokinetic effects may be diminished with the use of opioid analgesics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</p>\n<p>2. Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011.</p>\n<p>3. Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10842":"<p><b>Title</b> Lormetazepam / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Lormetazepam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid alcohol use in combination with lormetazepam.</p> \n<p><b>Discussion</b> In a study of 16 healthy volunteers, lormetazepam (2 mg single dose) reduced driving performance and increased reaction time compared with placebo.<sup>1</sup> The addition of alcohol (0.6 mg/kg) potentiated these effects.<sup>1</sup> Lormetazepam product labeling states that concomitant use of alcohol and lormetazepam is not recommended because the sedative effects may be enhanced when these agents are combined.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Willumeit HP, Ott H, Neubert W, Hemmerling KG, Schratzer M, Fichte K. Alcohol interaction of lormetzepam, mepindolol sulphate and diazepam measured by performance on the driving simulator. <i>Pharmacopsychiatry</i>. 1984;17(2):36-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6145169\">[PubMed 6145169]</a></p>\n<p>2. Dormagen (lormetazepam) [summary of product characteristics]. West Yorkshire, UK: Genus Pharmaceuticals; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10843":"<p><b>Title</b> Blood Pressure Lowering Agents / Lormetazepam</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lormetazepam may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hypotension if lormetazepam is initiated in patients taking blood pressure lowering agents</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Lormetazepam product labeling states that enhanced hypotensive effects may occur when lormetazepam is given to patients treated with antihypertensive agents.<sup>1</sup> Although hypotension has occurred only rarely, lormetazepam should be administered with caution to patients in whom a drop in blood pressure might lead to cardiovascular or cerebrovascular complications. This is particularly important in elderly patients.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dormagen (lormetazepam) [summary of product characteristics]. West Yorkshire, UK: Genus Pharmaceuticals; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10844":"<p><b>Title</b> Delamanid / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase electrocardiogram (ECG) monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors because the risk for QTc interval prolongation may be increased. Continue frequent ECG assessments throughout the full delamanid treatment period.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the AUC of delamanid was 22% higher in 16 subjects who received delamanid (100 mg twice daily) plus lopinavir/ritonavir (400 mg/100 mg twice daily) compared with the AUC of 15 subjects who received delamanid alone.<sup>1</sup> The AUC of the DM-6705 metabolite was 25% higher and the AUC of the DM-6704 metabolite was 75% higher among subjects who received concomitant lopinavir/ritonavir.<sup>1</sup><br><br>Delamanid product labeling states that because elevated serum concentrations of DM-6705 have been associated with QTc interval prolongation, the use of delamanid with strong CYP3A4 inhibitors must be accompanied by increased ECG monitoring.<sup>2</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme at least partially responsible for delamanid metabolism.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministration with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. <i>Antimicrob Agents Chemother</i>. 2016;60(10):5976-5985. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27458223\">[PubMed 27458223]</a></p>\n<p>2. Deltyba (delamanid) [summary of product characteristics]. Munich, Germany: Otsuka Novel Products GmbH; June 2015.</p>\n<p>3. Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. <i>Drug Metab Dispos</i>. 2015;43(8):1267-1276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26055620\">[PubMed 26055620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10845":"<p><b>Title</b> Delamanid / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of delamanid and strong CYP3A4 inducers. This combination is listed as a contraindication in delamanid product labeling.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the AUC and maximum serum concentration of delamanid were 47% and 42% lower, respectively, in 22 subjects who received delamanid (200 mg daily) plus a rifampin-containing antituberculosis regimen (rifampin [720 mg daily], ethambutol [1,100 mg daily], pyrazinamide [1,800 mg daily], and isoniazid [300 mg daily]) compared with those of 14 subjects who received delamanid alone.<sup>1</sup> The AUCs of delamanid's most prevalent metabolites (DM-6704, DM-6705, DM-6706, and DM-6722) were also 30% to 53% lower in subjects who received concomitant antituberculosis therapy.<sup>1</sup> <br><br>Delamanid product labeling states that in studies of healthy volunteers, exposure to delamanid was reduced up to 45% with the concomitant use of rifampin (300 mg daily) and delamanid (200 mg daily).<sup>2</sup> Therefore, use of delamanid with any strong CYP3A4 inducer is contraindicated.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated. Although CYP3A4 induction by rifampin may partially contribute, in vitro data suggest CYP3A4 does not play a major role in delamanid metabolism,<sup>3</sup> and in a clinical study, the concomitant use of the moderate CYP3A4 inducer efavirenz had no effect on delamanid exposure.<sup>2</sup> Decreased delamanid absorption may contribute, but the exact mechanism or which drug in the antituberculosis regimen may contribute most is unknown.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministration with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. <i>Antimicrob Agents Chemother</i>. 2016;60(10):5976-5985. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27458223\">[PubMed 27458223]</a></p>\n<p>2. Deltyba (delamanid) [summary of product characteristics]. Munich, Germany: Otsuka Novel Products GmbH; June 2015.</p>\n<p>3. Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. <i>Drug Metab Dispos</i>. 2015;43(8):1267-1276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26055620\">[PubMed 26055620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10846":"<p><b>Title</b> Delamanid / Quinolones</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Quinolones may enhance the QTc-prolonging effect of Delamanid. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable in order to construct an adequate treatment regimen for tuberculosis, then frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> In a clinical trial of patients with multidrug-resistant tuberculosis, patients were randomized to receive delamanid 100 mg twice daily, delamanid 200 twice mg daily, or placebo for 2 months in combination with a background anti-tuberculosis drug regimen.<sup>1</sup> Background anti-tuberculosis regimens contained a quinolone antibiotic in more than 96% of patients.<sup>1</sup> No cases of torsades de pointes were reported during the trial, but QTc prolongation occurred more frequently with delamanid 200 mg twice daily (13.1%) and with delamanid 100 mg twice daily (9.9%) compared with placebo (3.8%).<sup>1</sup> <br><br>Delamanid product labeling states that all QTc prolongations greater 60 msec were associated with concomitant fluoroquinolone use.<sup>2</sup> Therefore, if coadministration<br>is considered to be unavoidable in order to construct an adequate treatment regimen for tuberculosis, then frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. <i>N Engl J Med</i>. 2012;366(23):2151-2160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22670901\">[PubMed 22670901]</a></p>\n<p>2. Deltyba (delamanid) [summary of product characteristics]. Munich, Germany: Otsuka Novel Products GmbH; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10847":"<p><b>Title</b> Delamanid / Moxifloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Moxifloxacin (Systemic) may enhance the QTc-prolonging effect of Delamanid. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of delamanid and moxifloxacin.</p> \n<p><b>Discussion</b> In a clinical trial of patients with multidrug-resistant tuberculosis, patients were randomized to receive delamanid 100 mg twice daily, delamanid 200 twice mg daily, or placebo for 2 months in combination with a background anti-tuberculosis drug regimen.<sup>1</sup> Background anti-tuberculosis regimens contained a quinolone antibiotic in more than 96% of patients, but use of moxifloxacin was not permitted.<sup>1</sup> No cases of torsades de pointes were reported during the trial, but QTc prolongation occurred more frequently with delamanid 200 mg twice daily (13.1%) and with delamanid 100 mg twice daily (9.9%) compared with placebo (3.8%).<sup>1</sup> <br><br>Delamanid product labeling states that coadministration of moxifloxacin and delamanid has not been studied; therefore, moxifloxacin is not recommended for use in patients treated with delamanid.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. <i>N Engl J Med</i>. 2012;366(23):2151-2160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22670901\">[PubMed 22670901]</a></p>\n<p>2. Deltyba (delamanid) [summary of product characteristics]. Munich, Germany: Otsuka Novel Products GmbH; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10848":"<p><b>Title</b> Methotrexate / LevETIRAcetam</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LevETIRAcetam may increase the serum concentration of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum concentrations of methotrexate closely with use of this combination.</p> \n<p><b>Discussion</b> Two separate case reports describe methotrexate (MTX) toxicity and increased MTX concentrations following initiation of levetiracetam.<sup>1,2</sup> In one patient receiving high-dose MTX, the average time to elimination to nontoxic MTX levels was 130 hours with concurrent levetiracetam as compared to 90 hours prior to levetiracetam and 95 hours following discontinuation of levetiracetam and replacement with lorazepam.<sup>1</sup> In contrast, a retrospective review of 81 adults and 280 cycles of MTX that included 33 cycles with concurrent levetiracetam concluded that a clinically significant interaction between levetiracetam and MTX was unlikely.<sup>3</sup> According to this review, the 24-hour MTX concentration was an average of 61% lower with concurrent levetiracetam, but MTX concentrations at 48 and 72 hours were not different among levetiracetam recipients. Levetiracetam use was not a significant predictor of delayed MTX elimination.<br><br>A Health Canada safety review was published concerning this potential interaction, and this review noted 13 reports of a potential MTX interaction from the levetiracetam manufacturer, including 5 of which reported increased MTX concentrations.<sup>4</sup> This safety review recommends careful monitoring of both levetiracetam and MTX concentrations in patients receiving this combination.<br><br>The specific mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bain E, Birhiray RE, Reeves DJ. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination. <i>Ann Pharmacother</i>. 2014;48(2):292-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24259648\">[PubMed 24259648]</a></p>\n<p>2. Parentelli AS, Phulpin-Weibel A, Mansuy L, Contet A, Trechot P, Chastagner P. Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia. <i>Pediatr Blood Cancer</i>. 2013;60(2):340-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23129570\">[PubMed 23129570]</a></p>\n<p>3. Reeves D, DiDominick S, Finn S, Kim HJ, Shake A. Retrospective analysis of methotrexate elimination when coadministered with levetiracetam. <i>Ann Pharmacother</i>. 2016; Aug 10 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27511814\">[PubMed 27511814]</a></p>\n<p>4. Health Canada Safety Review. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/levetiracetam-eng.php. Accessed October 25, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10849":"<p><b>Title</b> Vitamin K Antagonists / Antihepaciviral NS5B RNA Polymerase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral NS5B RNA Polymerase Inhibitors may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor coagulation status more closely for several weeks after initiation of a NS5B polymerase inhibitor antihepaciviral agent. Anticoagulant dose adjustment may be required. Continued close monitoring of coagulation status after discontinuation of a NS5B polymerase inhibitor antihepaciviral is warranted.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n <p><b>Antihepaciviral NS5B RNA Polymerase Inhibitors Interacting Members</b> Dasabuvir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Sofosbuvir</p>\n</div> \n<p><b>Discussion</b> The warfarin sensitivity index (WSI) (INR/daily dose) was an average of 23% lower following treatment for hepatitis C virus (HCV) with a direct-acting antiviral (DAA) according to a retrospective cohort study of 271 veterans chronically maintained on warfarin.<sup>1</sup> The mean weekly warfarin dose increased by 15% from pre-DAA treatment to post-treatment. The biggest decreases in mean INR were seen within the first 3 weeks of therapy. For the 229 patients treated with a sofosbuvir-containing regimen (sofosbuvir, n=43; sofosbuvir and ledipasvir, n=168; sofosbuvir and simeprevir, n=18), the mean WSI decreased between 9.4% and 15.1%. For the 42 patients treated with an ombitasvir/paritaprevir/ritonavir and dasabuvir-containing regimen, the WSI decreased by an average of 32%. Concurrent ribavirin was used by 62% of patients, and use of ribavirin was associated with an average 16.9% additional decrease in WSI.<sup>1</sup> Twelve weeks after HCV therapy discontinuation, the WSI increased back towards baseline, but remained 10% to 12% below baseline in both groups.<sup>2</sup> <br><br>A case series describes four patients chronically maintained on warfarin who required 14% to 67% warfarin dose increases following initiation of DAA therapy consisting of ledipasvir/sofosbuvir.<sup>3</sup> Three of the four patients were receiving concurrent ribavirin. Two patients required warfarin dose reductions following completion of DAA therapy, while the other two patients did not. Similarly, a case report describes a 61-year-old male maintained on a stable acenocoumarol dose (8 mg/week for 4 months and 8 to 9.5 mg/week for the two years prior to that) for double valve replacement (target INR 2.5 to 3.5) who experienced a decrease in INR from 3 at baseline to 1.4 four weeks following initiation of DAA therapy with ombitasvir/paritaprevir/ritonavir (25/150/100 mg orally daily), dasabuvir (250 mg orally twice daily) and ribavirin (400 mg orally twice daily).<sup>4</sup> The patient required a 137.5% increase in acenocoumarol dose by end of DAA treatment and eight weeks of bridge therapy with enoxaparin. His INR increased to 4.5 two weeks following DAA therapy completion, and despite continued acenocoumarol dose adjustments, the patient experienced a spontaneous varicose vein bleed at one month following DAA completion. In another report a 58-year-old man stable on warfarin (40 mg per week, INR 2.0 to 2.5), experienced an INR of 1.2 two weeks after initiation of ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin, and required a warfarin dose increase of 125% (90 mg per week) in order to reach a therapeutic INR.<sup>5</sup> Two weeks after completion of DAA therapy, his INR rose to 7.3. After holding warfarin for several days and decreasing the warfarin dose (42.5 mg per week), his INR stabilized in the therapeutic range.<sup>5</sup> A decrease in INR and subsequent thrombosis was also noted after initiation of sofosbuvir/velpatasvir in a warfarin treated patient.<sup>6</sup><br><br>The specific mechanism for this apparent interaction is unknown, as is the contribution of some of the concurrent antivirals that were present in some cases. Improvement of liver function via treatment of HCV has been suggested as at least a contributing factor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. <i>Ann Pharmacother</i>. 2016;50(11):909-917. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27465881\">[PubMed 27465881]</a></p>\n<p>2. DeCarolis DD, Chen YC, Westanmo AD. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin: twelve-week post-treatment follow-up. <i>Ann Pharmacother</i>. 2017;51(5):439-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28100063\">[PubMed 28100063]</a></p>\n<p>3. Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of successful chronic hepatitis C virus treatment with ledipasvir/sofosbuvir on warfarin dosing requirements in four veterans. <i>Pharmacotherapy</i>. 2016 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27716978\">[PubMed 27716978]</a></p>\n<p>4. de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, et al. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. <i>J Clin Pharm Ther</i>. 2016;41(4):444-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27159430\">[PubMed 27159430]</a></p>\n<p>5. Puglisi GM, Smith SM, Jankovich RD, Ashby CR Jr, Jodlowski TZ. Paritaprevir/ritonavir/ombitasvir/dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report [published online November 3, 2016]. <i>J Clin Pharm Ther</i>. Doi: 10.1111/jcpt.12475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27813106\">[PubMed 27813106]</a></p>\n<p>6. Rindone JP, Mellen CK. Reduction in warfarin effect associated with sofosbuvir-velpatasvir. <i>Am J Health Syst Pharm</i>. 2017;74(17):1308-1311.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10850":"<p><b>Title</b> Vitamin K Antagonists / Ribavirin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ribavirin (Systemic) may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor coagulation status more closely for several weeks after initiation of ribavirin. Anticoagulant dose adjustment may be required. Continued close monitoring of coagulation status after discontinuation of ribavirin is warranted.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The warfarin sensitivity index (WSI) (INR/daily dose) was an average of 23% lower following treatment for hepatitis C virus (HCV) with a direct-acting antiviral (DAA) according to a retrospective cohort study of 271 veterans chronically maintained on warfarin.<sup>1</sup> The mean weekly warfarin dose increased by 15% from pre-DAA treatment to post-treatment. The biggest decreases in mean INR were seen within the first 3 weeks of therapy. For the 229 patients treated with a sofosbuvir-containing regimen (sofosbuvir, n=43; sofosbuvir and ledipasvir, n=168; sofosbuvir and simeprevir, n=18), the mean WSI decreased between 9.4% and 15.1%. For the 42 patients treated with an ombitasvir/paritaprevir/ritonavir and dasabuvir-containing regimen, the WSI decreased by an average of 32%. Concurrent ribavirin was used by 62% of patients, and use of ribavirin was associated with an average 16.9% additional decrease in WSI.<br><br>A case series describes four patients chronically maintained on warfarin who required 14% to 67% warfarin dose increases following initiation of DAA therapy consisting of ledipasvir/sofosbuvir.<sup>2</sup> Three of the four patients were receiving concurrent ribavirin. Two patients required warfarin dose reductions following completion of DAA therapy, while the other two patients did not. Similarly, a case report describes a 61-year-old male maintained on a stable acenocoumarol dose (8 mg/week for 4 months and 8 to 9.5 mg/week for the two years prior to that) for double valve replacement (target INR 2.5 to 3.5) who experienced a decrease in INR from 3 at baseline to 1.4 four weeks following initiation of DAA therapy with ombitasvir/paritaprevir/ritonavir (25/150/100 mg orally daily), dasabuvir (250 mg orally twice daily) and ribavirin (400 mg orally twice daily).<sup>3</sup> The patient required a 137.5% increase in acenocoumarol dose by end of DAA treatment and eight weeks of bridge therapy with enoxaparin. His INR increased to 4.5 two weeks following DAA therapy completion, and despite continued acenocoumarol dose adjustments, the patient experienced a spontaneous varicose vein bleed at one month following DAA completion. Another published case report describes a patient treated with interferon and ribavirin who required a 40% warfarin dose increase within 4 weeks of starting the antiviral regimen.<sup>4</sup> A subsequent rechallenge with ribavirin replicated the impact on warfarin effectiveness and dose requirement.<br><br>The specific mechanism for this apparent interaction is unknown, as is the contribution of some of the concurrent antivirals that were present in some cases. Improvement of liver function via treatment of HCV has been suggested as at least a contributing factor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. <i>Ann Pharmacother</i>. 2016 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27465881\">[PubMed 27465881]</a></p>\n<p>2. Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of successful chronic hepatitis C virus treatment with ledipasvir/sofosbuvir on warfarin dosing requirements in four veterans. <i>Pharmacotherapy</i>. 2016 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27716978\">[PubMed 27716978]</a></p>\n<p>3. de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, et al. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. <i>J Clin Pharm Ther</i>. 2016;41(4):444-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27159430\">[PubMed 27159430]</a></p>\n<p>4. Schulman S. Inhibition of warfarin activity by ribavirin. <i>Ann Pharmacother</i>. 2002;36(1):72-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11816263\">[PubMed 11816263]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10851":"<p><b>Title</b> Valproate Products / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may decrease the serum concentration of Valproate Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor valproate concentrations and effects carefully with concurrent use of an estrogen-containing contraceptive, particularly when starting or stopping the estrogen.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> Total and free serum valproate concentrations were an average of 18% and 29% lower, respectively, when measured during concurrent use of active ethinylestradiol-containing contraceptives than when measured after a 4- or 7-day hormonal contraceptive-free period in a study of 9 women.<sup>1</sup> A case report similarly describes a patient who, during 2 separate cycles, experienced total valproate concentrations that were 36% and 61% lower during use of an ethinylestradiol-containing contraceptive than after 5 or 7 days of inactive tablets.<sup>2</sup> A record of the patient's seizure activity also showed that she experienced 12 seizures during 105 days of active ethinylestradiol-containing contraceptive use but zero seizures during 35 days of inactive tablet use.<br><br>Prescribing information for valproate products warn that estrogen-containing contraceptives may decrease valproate concentrations, possibly resulting in increased seizure frequency.<sup>3</sup> Increased monitoring of valproate concentrations and effects, particularly when starting or stopping concurrent use of an estrogen-containing product, is recommended.<br><br>The specific mechanism for this interaction is uncertain, but it has been suggested that estrogens may increase valproate clearance, possibly by induction of valproate glucuronidation.<sup>1,3</sup><br><br>A study in 6 subjects has shown that sodium valproate (200 mg twice/day for 2 to 4 months) had no significant effect on ethinylestradiol concentrations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Galimberti CA, Mazzucchelli I, Arbasino C, Canevini MP, Fattore C, Perucca E. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. <i>Epilepsia</i>. 2006;47(9):1569-1572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16981874\">[PubMed 16981874]</a></p>\n<p>2. Herzog AG, Farina EL, Blum AS. Serum valproate levels with oral contraceptive use. <i>Epilepsia</i>. 2005;46(6):970-971. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15946343\">[PubMed 15946343]</a></p>\n<p>3. Depakote (divalproex) [prescribing information]. North Chicago, IL: AbbVie Inc.; September 2016.</p>\n<p>4. Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. <i>Contraception</i>. 1986;33(1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3082590\">[PubMed 3082590]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10852":"<p><b>Title</b> Repaglinide / Leflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Leflunomide may increase the serum concentration of Repaglinide. Specifically, the active metabolite of leflunomide may increase repaglinide concentrations. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring of repaglinide response when used with leflunomide. In addition, caution patients to be alert for possible increased repaglinide effects. Due to the long half-life of the the active metabolite of leflunomide, teriflunomide (2-3 weeks), any interaction could persist for several weeks-months after the last dose of leflunomide.</p> \n<p><b>Discussion</b> Data concerning this specific combination are not available, but teriflunomide, which is the active metabolite of leflunomide, has been shown to interact with repaglinide. The repaglinide AUC and maximum serum concentration (Cmax) were increased by an average of 2.4- and 1.7-fold, respectively, when a single dose of repaglinide (0.25 mg) was administered following repeated doses of teriflunomide.<sup>1,2</sup><br><br>The likely mechanism for this reported interaction is inhibition of the CYP2C8-mediated metabolism of repaglinide by teriflunomide, which is characterized as a moderate inhibitor of CYP2C8.<sup>1,2</sup> Due to the long half-life of the teriflunomide (2-3 weeks), any interaction could persist for several weeks-months after the last dose of teriflunomide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Arava (leflunomide) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; October 2016.</p>\n<p>1. Aubagio (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10853":"<p><b>Title</b> Modafinil / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may diminish the therapeutic effect of Modafinil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients taking modafinil to avoid concurrent use of alcohol.</p> \n<p><b>Discussion</b> According to the modafinil prescribing information, patients taking modafinil should be advised to avoid concurrent use of alcohol.<sup>1</sup> The prescribing information notes that the combination has not been studied.<br><br>Alcohol is a CNS depressant and would be expected to oppose the effects of modafinil.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10854":"<p><b>Title</b> Armodafinil / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may diminish the therapeutic effect of Armodafinil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients taking armodafinil to avoid concurrent use of alcohol.</p> \n<p><b>Discussion</b> According to the armodafinil prescribing information, patients taking armodafinil should be advised to avoid concurrent use of alcohol.<sup>1</sup> The prescribing information notes that the combination has not been studied.<br><br>Alcohol is a CNS depressant and would be expected to oppose the effects of armodafinil.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nuvigil (armodafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10855":"<p><b>Title</b> Lofepramine / Entacapone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Entacapone may enhance the adverse/toxic effect of Lofepramine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of lofepramine and entacapone.</p> \n<p><b>Discussion</b> Lofepramine UK labeling states that concomitant use of entacapone should be avoided.<sup>1,2</sup> No specific data to support this warning is included in the labeling, although there is a general caution about use with dopaminergics. Of possible relevance, a study in 12 healthy female subjects reported no evidence of an interaction between entacapone 200 mg and imipramine, which is a tertiary tricyclic antidepressant that is structurally similar to lofepramine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lofepramine [summary of product characteristics]. Barnstaple, North Devon, United Kingdom: Arrow Generics Limited; March 2014.</p>\n<p>2. Lofepramine [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; January 2016.</p>\n<p>3. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. <i>Eur J Clin Pharmacol</i>. 1996;51(3-4):273-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9010698\">[PubMed 9010698]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10856":"<p><b>Title</b> Amiodarone / Lofepramine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lofepramine may enhance the arrhythmogenic effect of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of lofepramine and amiodarone.</p> \n<p><b>Discussion</b> Lofepramine UK labeling states that concomitant use of amiodarone should be avoided.<sup>1,2</sup> Although specific data supporting this recommendation is not provided, this appears to be out of concern for a possible increased risk for QT-prolongation and associated ventricular arrhythmias. Specific data concerning the potential for lofepramine to prolong the QT interval are not provided, but tricyclic antidepressants, in general, are considered to increase the risk of QT-prolongation. Amiodarone has a high risk for QT-prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lofepramine [summary of product characteristics]. Barnstaple, North Devon, United Kingdom: Arrow Generics Limited; March 2014.</p>\n<p>2. Lofepramine [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10857":"<p><b>Title</b> Terfenadine / Lofepramine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lofepramine may enhance the arrhythmogenic effect of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of lofepramine and terfenadine.</p> \n<p><b>Discussion</b> Lofepramine UK labeling states that concomitant use of terfenadine should be avoided.<sup>1,2</sup> Although specific data supporting this recommendation is not provided, this appears to be out of concern for a possible increased risk for QT-prolongation and associated ventricular arrhythmias. Specific data concerning the potential for lofepramine to prolong the QT interval are not provided, but tricyclic antidepressants, in general, are considered to increase the risk of QT-prolongation. Terfenadine has a high risk for QT-prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lofepramine [summary of product characteristics]. Barnstaple, North Devon, United Kingdom: Arrow Generics Limited; March 2014.</p>\n<p>2. Lofepramine [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10858":"<p><b>Title</b> Pimozide / Lofepramine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lofepramine may enhance the arrhythmogenic effect of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of lofepramine and pimozide.</p> \n<p><b>Discussion</b> Lofepramine UK labeling states that concomitant use of pimozide should be avoided.<sup>1,2</sup> Although specific data supporting this recommendation is not provided, this appears to be out of concern for a possible increased risk for QT-prolongation and associated ventricular arrhythmias. Specific data concerning the potential for lofepramine to prolong the QT interval are not provided, but tricyclic antidepressants, in general, are considered to increase the risk of QT-prolongation. Pimozide has a high risk for QT-prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lofepramine [summary of product characteristics]. Barnstaple, North Devon, United Kingdom: Arrow Generics Limited; March 2014.</p>\n<p>2. Lofepramine [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10859":"<p><b>Title</b> Nitroglycerin / Anticholinergic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is specific to nitroglycerin sublingual tablets. Other nitroglycerin dosage forms are not likely to be impacted by concurrent anticholinergic agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that sublingual nitroglycerin tablets may not dissolve as well or as rapidly in patients with a dry mouth, so patients who experience a dry mouth as a result of the use of anticholinergic agents should consider actions to increase saliva production (chewing gum and use of artificial saliva products are recommended in sublingual nitroglycerin labeling as examples of such actions).</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Published reports describe patients who have experienced delayed response to sublingual nitroglycerin that was attributed to anticholinergic medication-related dry mouth.<sup>1,2</sup> Patients with dry mouth experienced delayed pain relief and resolution of ST-segment depression with sublingual nitroglycerin tablets than with sublingual spray in a study in which patients with angina were assessed for dry mouth and divided into 2 groups based on mouth dryness.<sup>3</sup><br><br>The labeling for sublingual nitroglycerin tablets states that anticholinergic agents may impair the dissolution of the nitroglycerin sublingual tablets due to decreased salivary secretions, which is a known side effect of anticholinergic agents.<sup>4</sup> The labeling recommends that patients should consider actions to increase saliva production (chewing gum and use of artificial saliva products are recommended in sublingual nitroglycerin labeling as examples of such actions).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dry mouth and delayed dissolution of nitroglycerin. <i>N Engl J Med</i>. 1984;310(17):1122-1123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6424013\">[PubMed 6424013]</a></p>\n<p>2. Robbins LJ. Dry mouth and delayed dissolution of sublingual nitroglycerin. <i>N Engl J Med</i>. 1983;309(16):985. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6413859\">[PubMed 6413859]</a></p>\n<p>3. Sato H, Koretsune Y, Taniguchi T, et al. Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial. <i>Arzneimittelforschung</i>. 1997;47(2):128-131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9079231\">[PubMed 9079231]</a></p>\n<p>4. Nitrostat (nitroglycerin) sublingual tablets [prescribing information]. New York, NY: Pfizer Inc; May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10860":"<p><b>Title</b> Diethylstilbestrol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Diethylstilbestrol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced diethylstilbestrol effects if used together with a strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> At least one diethylstilbestrol (DES) label states that concurrent use with enzyme inducers such as rifampin, phenytoin, or barbiturates may induce metabolism of DES, possibly reducing the effectiveness of DES treatment.<sup>1</sup><br><br>While specific data with DES and these agents are not provided, there are data with other estrogen derivatives. The AUC of ethinyl estradiol was decreased by 62.5% in 12 females taking an estrogen-containing oral contraceptive (also including norethindrone) when coadministered with rifampin on cycle days 7-21.<sup>2</sup> Pharmacokinetics of single doses of ethinyl estradiol and levonorgestrel were studied in 4 women both before, and 8-12 weeks after, the initiation of carbamazepine therapy.<sup>3</sup> The serum concentrations of ethinyl estradiol and levonorgestrel were reduced 42% and 40%, respectively, in the presence of the carbamazepine.<br><br>The mechanism of this interaction is not certain, but induction of CYP3A4 is the likely mechanism, as DES is reportedly metabolized in a similar manner as other estrogens.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Destilbenol (diethylstilbestrol) tablets [prescribing information]. Sao Paulo, Brazil: Pharmaceutical Aspens S/A.</p>\n<p>2. Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. <i>Clin Pharmacol Ther</i>. 1999;65(4):428-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223781\">[PubMed 10223781]</a></p>\n<p>3. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. <i>Br J Clin Pharmacol</i>. 1990;30(6):892-896. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2126946\">[PubMed 2126946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10861":"<p><b>Title</b> Dantrolene / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor carefully for evidence of hepatotoxicity with concurrent use of dantrolene with an estrogen derivative, particularly in women over 35 years of age.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The dantrolene labeling states that hepatotoxicity appears to occur more often in women over 35 years of age who are receiving an estrogen.<sup>1</sup> The labeling for at least one estrogen derivative also warns that concurrent use with dantrolene may increase the risk for hepatotoxicity.<sup>2</sup><br><br>The specific mechanism of this interaction is not certain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dantrium (dantrolene) [prescribing information]. Rochester, MI: JHP Pharmaceuticals, LLC; October 2011.</p>\n<p>2. Destilbenol (diethylstilbestrol) tablets [prescribing information]. Sao Paulo, Brazil: Pharmaceutical Aspens S/A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10862":"<p><b>Title</b> Bromocriptine / Diethylstilbestrol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diethylstilbestrol may enhance the adverse/toxic effect of Bromocriptine. Specifically, the risk for amenorrhea may be increased with the combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of this combination may increase the risk for amenorrhea.</p> \n<p><b>Discussion</b> The diethylstilbestrol (DES) labeling states that concurrent use of bromocriptine may increase the risk for amenorrhea.<sup>1</sup><br><br>The specific mechanism of this interaction is not certain. Bromocriptine is used to treat certain cases of amenorrhea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dantrium (dantrolene) [prescribing information]. Rochester, MI: JHP Pharmaceuticals, LLC; October 2011.</p>\n<p>2. Destilbenol (diethylstilbestrol) tablets [prescribing information]. Sao Paulo, Brazil: Pharmaceutical Aspens S/A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10863":"<p><b>Title</b> Loprazolam / Cisapride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cisapride may enhance the therapeutic effect of Loprazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that the effects of loprazolam may be greater or may appear more rapidly when used with cisapride. Monitor for evidence of increased loprazolam adverse effects.</p> \n<p><b>Discussion</b> The loprazolam labeling states that concurrent use of cisapride may potentiate the effect of loprazolam.<sup>1</sup><br><br>The specific mechanism of this interaction is not certain. Cisapride may alter the rate of loprazolam absorption via its ability to increase gastric motility.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dormonoct (loprazolam) [prescribing information]. Guildford, Surrey, United Kingdom: Winthrop Pharmaceuticals UK Limited; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10865":"<p><b>Title</b> Chloral Betaine / Furosemide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Furosemide may enhance the adverse/toxic effect of Chloral Betaine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. The U.S. and some international labeling for furosemide recommend against concurrent use with chloral hydrate, which is the active product resulting from chloral betaine administration. Close monitoring for evidence of toxicity is recommended if combined use cannot be avoided.</p> \n<p><b>Discussion</b> The labeling for chloral betaine states that concurrent use of chloral hydrate (which is the active product present following administration of chloral betaine) and furosemide has been associated with adverse effects including sweating, flushing, and variable blood pressure.<sup>1</sup><br><br>A case report describes a 68-year-old woman who received furosemide 80 mg IV 1 hour before and 12 hours after receiving chloral hydrate 500 mg and experienced flushing, tachycardia, increased blood pressure, and diaphoresis immediately after the second furosemide dose.<sup>2</sup> For the next several days the patient received furosemide, but no chloral hydrate, without incident. On day 5, the patient experienced recurrence of the prior symptoms 8 hours after chloral hydrate 500 mg and immediately after receiving furosemide 40 mg IV. A case report describes similar symptoms (diaphoresis, tachycardia, and agitation) within 5 minutes of IV administration of furosemide to an 8 year old male receiving chloral hydrate.<sup>3</sup> A resolution of symptoms was observed within 15-20 minutes.<br><br>The specific mechanism for this is uncertain, but it has been proposed that trichloroacetic acid, a highly protein-bound metabolite of chloral hydrate, may displace thyroxin from its protein binding sites resulting in a hypermetabolic state.<sup>1,2</sup> The U.S. and Canadian furosemide product labeling recommend against concurrent use of furosemide with chloral hydrate.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Welldorm (cloral betaine) [summary of product characteristics]. Marlborough, Wiltshire, United Kingdom: Marlborough Pharmaceuticals Ltd; December 2014.</p>\n<p>2. Malach M, Berman N. Furosemide and chloral hydrate. Adverse drug interaction. <i>JAMA</i>. 1975;232(6):638-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1173156\">[PubMed 1173156]</a></p>\n<p>3. Dean RP, Rudinsky BF, Kelleher MD. Interaction of chloral hydrate and intravenous furosemide in a child. <i>Clin Pharm</i>. 1991;10(5):385-387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2049901\">[PubMed 2049901]</a></p>\n<p>3. Lasix (furosemide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, January 2011.</p>\n<p>4. Lasix (furosemide) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10866":"<p><b>Title</b> Vitamin K Antagonists / Chloral Betaine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloral Betaine may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor closely for increased effects of vitamin K antagonists (eg, PT/INR and signs and symptoms of bleeding) when starting or stopping concurrent chloral hydrate (which is the active product present after chloral betaine administration). The risk for increased effects of vitamin K antagonists are thought to be transient, occuring within the first few days or weeks following initiation of chloral hydrate. Temporary dose reductions of the vitamin K antagonist may be necessary.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The warfarin dose requirement on days 2 to 4 of therapy was an average of 31% lower among patients receiving daily chloral hydrate for the first 4 days of warfarin therapy (n=32) as compared to those patients not receiving any chloral hydrate during the first 4 days (n=67) as part of a retrospective review.<sup>1</sup> The dose requirement on days 2 to 4 was an average of 17% lower among patients receiving only 1 to 3 doses of chloral hydrate during the first 4 days of warfarin. Both the warfarin loading dose and the warfarin maintenance dose were not different among the groups. This is similar to other reports describing a transient increase in warfarin effects with concurrent use of chloral hydrate.<sup>2,3</sup><br><br>Conversely, several other studies have reported no evidence of a significant interaction between chloral hydrate and warfarin, including specifically a lack of any evidence for even a transient interaction.<sup>3,4,5</sup><br><br>The mechanism of any potential interaction is uncertain, but displacement of warfarin from its protein binding sites by a highly-bound chloral hydrate metabolite may be at least partially responsible for any transient increase in warfarin effects. Some chloral hydrate labeling warns that a transient enhancement of coumarin hypoprothrombinemic effects may occur within the first two weeks of therapy due to displacement of the anticoagulant from plasma binding proteins.<sup>6</sup> Chloral betaine labeling more generally recommends close monitoring of the anticoagulant response following the initiation or discontinuation of chloral hydrate.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Interaction between chloral hydrate and warfarin. A report from the Boston Collaborative Drug Surveillance Program, Boston Universtiy Medical Center. <i>N Engl J Med</i>. 1972;286(2):53-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5006877\">[PubMed 5006877]</a></p>\n<p>2. Sellers EM, Koch-Weser J. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. <i>N Engl J Med</i>. 1970;283(16):827-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5458032\">[PubMed 5458032]</a></p>\n<p>3. Koch-Weser J, Sellers EM, Udall JA, Griner PF, Rickles FR. Chloral hydrate and warfarin therapy. <i>Ann Intern Med</i>. 1971;75(1):141-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5091561\">[PubMed 5091561]</a></p>\n<p>4. Udall JA. Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance. <i>Ann Intern Med</i>. 1974;81(3):341-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4855407\">[PubMed 4855407]</a></p>\n<p>5. Griner PF, Raisz LG, Rickles FR, Wiesner PJ, Odoroff CL. Chloral hydrate and warfarin interaction: clinical significance. <i>Ann Intern Med</i>. 1971;74(4):540-543. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4927901\">[PubMed 4927901]</a></p>\n<p>6. pms-Chloral hydrate [product monograph]. Montreal, Canada: Pharmascience Inc.; May 1998.</p>\n<p>7. Welldorm (cloral betaine) [summary of product characteristics]. Marlborough, Wiltshire, United Kingdom: Marlborough Pharmaceuticals Ltd; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10867":"<p><b>Title</b> Anticholinergic Agents / Chloral Betaine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloral Betaine may enhance the adverse/toxic effect of Anticholinergic Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor carefully for development or worsening of delirium with use of chloral betaine together with an anticholinergic agent.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The labeling for cloral betaine states that concurrent use of anticholinergic agents with chloral hydrate (which is the active product present following administration of chloral betaine) has been associated with delirium.<sup>1</sup> The specific magnitude of this risk is not specified, and the mechanism for this reported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Welldorm (cloral betaine) [summary of product characteristics]. Marlborough, Wiltshire, United Kingdom: Marlborough Pharmaceuticals Ltd; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10870":"<p><b>Title</b> BCRP/ABCG2 Substrates / Tedizolid</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered BCRP substrates when combined with orally administered tedizolid.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tedizolid may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of orally administered BCRP substrates if combined with oral tedizolid. If the BCRP substrate has a narrow therapeutic index, consider stopping treatment with the BCRP substrate during treatment with tedizolid.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the tedizolid prescribing information, oral tedizolid (200 mg daily for multiple days) increased the rosuvastatin (10 mg single dose) AUC and maximum serum concentration 70% and 55%, respectively.<sup>1</sup><br><br>Tedizolid prescribing information states that because oral tedizolid inhibits BCRP in the intestine, it may increase concentrations of orally administered BCRP substrates and lead to adverse effects.<sup>1</sup> <br><br>The suspected mechanism of this interaction is tedizolid-mediated inhibition of BCRP, a transporter responsible for rosuvastatin disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sivextro (tedizolid) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10871":"<p><b>Title</b> Propofol / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the therapeutic effect of Propofol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased propofol effects when combined with valproate products. Decreased propofol doses may be required.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> In a study involving 33 patients with bipolar affective disorder undergoing electroconvulsive therapy (ECT), the required propofol dose was approximately 31% lower in patients receiving valproic acid (n=17) compared with patients not receiving valproic acid (n=16).<sup>1</sup> In another study involving 45 patients with moderate to severe mental retardation undergoing dental procedure-related sedation, the median propofol dose was 27% lower in patients receiving valproic acid (n=20) compared with patients not receiving valproic acid (n=25).<sup>2</sup> The lower propofol dose requirement in patients receiving valproic acid persisted when accounting for concurrent administration of enzyme inducing anticonvulsants.<sup>2</sup><br><br>Prescribing information for valproate products states that concomitant use of valproate and propofol may lead to increased blood levels of propofol.<sup>3,4</sup> Patients should be closely monitored for signs of increased sedation or cardiorespiratory depression and the dose of propofol should be reduced if necessary.<sup>3,4</sup><br><br>The mechanism of this interaction has not been fully investigated. Valproate mediated inhibition of UDP-glucuronosyltransferase 1A9 or CYP2C9, enzymes involved in propofol metabolism, may contribute.<sup>1,2</sup> Additionally, because valproate and propofol both act on gamma-aminobutyric acid (GABA) receptors, their synergistic effects may reduce propofol dose requirements.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hizli Sayar G, Eryilmaz G, Semieoglu S, Ozten E, Gogcegoz Gul I. Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients. <i>Neuropsychiatr Dis Treat</i>. 2014;10:433-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24623978\">[PubMed 24623978]</a></p>\n<p>2. Ishii M, Higuchi H, Maeda S, Tomoyasu Y, Equsa M, Miyawaki T. The influence of oral VPA on the required dose of propofol for sedation during dental treatment in patients with mental retardation: a prospective observer-blinded cohort study. <i>Epilepsia</i>. 2012;53(1):e13-e16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22091873\">[PubMed 22091873]</a></p>\n<p>3. Depakene (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2016.</p>\n<p>4. Depakote (divalproex) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10872":"<p><b>Title</b> Dasabuvir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir with or without dasabuvir) and strong CYP3A4 inducers is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, the strong CYP3A4 inducer carbamazepine (200 mg once daily titrated to 200 mg twice daily) decreased the AUC of ombitasvir 31%, paritaprevir 70%, ritonavir 87%, and dasabuvir 70% when given with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product in 12 healthy volunteers.<sup>1,2</sup> The maximum serum concentration of ombitasvir, paritaprevir, ritonavir, and dasabuvir decreased 31%, 66%, 83%, and 55%, respectively.<sup>1,2</sup><br><br>Product labeling for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) state that use with strong CYP3A4 inducers is contraindicated due to decreased exposure of each component and the potential loss of therapeutic efficacy.<sup>1,2</sup><br><br>The mechanism of this interaction is likely increased CYP3A4 mediated metabolism, an enzyme responsible for paritaprevir, ritonavir, and dasabuvir metabolism. Induction of P-glycoprotein and CYP2C8 may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10873":"<p><b>Title</b> Dasabuvir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) and moderate CYP3A4 inducers is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, the strong CYP3A4 inducer carbamazepine (200 mg once daily titrated to 200 mg twice daily) decreased the AUC of ombitasvir 31%, paritaprevir 70%, ritonavir 87%, and dasabuvir 70% when given with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product in 12 healthy volunteers.<sup>1,2</sup> The maximum serum concentration of ombitasvir, paritaprevir, ritonavir, and dasabuvir decreased 31%, 66%, 83%, and 55%, respectively.<sup>1,2</sup><br><br>Product labeling for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) state that use with moderate CYP3A4 inducers is contraindicated due to the potential for decreased exposure of each component and the loss of therapeutic efficacy.<sup>1,2</sup><br><br>The mechanism of this interaction is likely increased CYP3A4 mediated metabolism, an enzyme responsible for paritaprevir, ritonavir, and dasabuvir metabolism. Induction of P-glycoprotein may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10874":"<p><b>Title</b> Dasabuvir / Ethinyl Estradiol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ethinyl Estradiol may enhance the hepatotoxic effect of Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ethinyl estradiol with antihepaciviral combination products is contraindicated. Use of ethinyl estradiol must be discontinued prior to use of this combination; ethinyl estradiol can be restarted 2 weeks after cessation of the antihepaciviral combination product. It is unclear if other estrogens convey a similar increase in risk, but the limited available data suggest no significant increase in risk. Any such combinations should be used with caution.</p> \n<p><b>Discussion</b> The incidence of elevated alanine aminotransferase (ALT) concentrations in patients taking the ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir combination products was significantly higher among those who were also treated with ethinyl estradiol.<sup>1,2</sup> The incidence of ALT concentrations at least 5 times the upper limit of normal with use of ombitasvir/paritaprevir/ritonavir/dasabuvir was approximately 1%, but among the small number of patients also using ethinyl estradiol the incidence was 25% (4/16).<sup>1</sup> Available data suggest that a similar risk among patients using other estrogens (3%; 2/59) may be possible.<br><br>The specific mechanism for this potential interaction is unknown. Similarly, whether this increased risk is attributed to one or multiple components in the antihepaciviral combination products is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10876":"<p><b>Title</b> Dasabuvir / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of ombitasvir/paritaprevir/ritonavir/dasabuvir and strong CYP2C8 inhibitors is contraindicated and should be avoided.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information, the concomitant use of paritaprevir/ritonavir/dasabuvir and the strong CYP2C8 inhibitor gemfibrozil (600 mg twice daily) increased the dasabuvir AUC and maximum serum concentration 11.3-fold and 2.0-fold, respectively.<sup>1</sup><br><br>The prescribing information for ombitasvir/paritaprevir/ritonavir/dasabuvir states that due to the risk of increased QTc prolongation associated with increased dasabuvir exposure, the use of gemfibrozil or any other strong CYP2C8 inhibitor with ombitasvir/paritaprevir/ritonavir/dasabuvir is contraindicated.<br><br>The mechanism of this interaction is CYP2C8 inhibition by gemfibrozil, an enzyme responsible for dasabuvir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10877":"<p><b>Title</b> Rosuvastatin / Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US labeling recommends limiting the rosuvastatin dose to 10 mg daily. Labeling outside of the US recommends limiting the rosuvastatin dose to 5 mg daily.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dasabuvir may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the rosuvastatin dose to a maximum of 10 mg per day when used with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product. Monitor patients closely for evidence of rosuvastatin toxicities (eg, myopathy). Labeling outside of the US recommends limiting the rosuvastatin dose to 5 mg per day.</p> \n<p><b>Discussion</b> The rosuvastatin AUC was an average of 2.59-fold higher with concurrent use of the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.<sup>1</sup> Based on these changes and concerns over an increased risk for rosuvastatin toxicities, the US prescribing information for the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product recommends limiting the rosuvastatin dose to a maximum of 10 mg per day.<sup>1</sup> Canadian labeling recommends limiting the rosuvastatin dose to 5 mg per day.<sup>2</sup> <br><br>The most likely mechanism for this interaction is inhibition of the SLCO1B1 (aka OATP1B1) uptake transporter by paritaprevir leading to reduced hepatic uptake of rosuvastatin. The disposition of many statins, including rosuvastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1, and paritaprevir has been shown to inhibit SLCO1B1 activity.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p>3. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. <i>Drug Metab Dispos</i>. 2008;36(10):2014-2023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18617601\">[PubMed 18617601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10878":"<p><b>Title</b> Clindamycin (Systemic) / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Clindamycin (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 34 patients with severe osteoarticular infections randomly assigned to receive clindamycin (600 mg orally 3 times daily) with either levofloxacin (500 mg orally daily) or the strong CYP3A4 inducer rifampin (600 mg orally twice daily) for 30 days, rifampin coadministration was associated with average decreases in maximum and minimum clindamycin serum concentrations of 66% and 83%, respectively.<sup>1</sup> Clinical cure rates at a mean of 23 months (n=24 patients) were similar between treatments. Consistent with these results, mean minimum clindamycin plasma concentrations were 70% lower in patients (n=6) receiving rifampin-containing regimens in a retrospective observational analysis of 61 patients hospitalized with osteoarticular infections,<sup>2</sup> and mean clindamycin concentrations were 40% lower in patients receiving concomitant rifampin (n=56) in a study of 70 patients receiving intravenous clindamycin infusion for treatment of osteoarticular infections.<sup>3</sup> Additionally, clindamycin maximum and minimum serum concentrations were lower by 82% and 92%, respectively, in a report of data from 10 patients receiving clindamycin with rifampin compared with historical control patients receiving clindamycin alone.<sup>4</sup><br><br>Despite the potential for a substantial pharmacokinetic interaction between rifampin and clindamycin, no clinically detrimental effects have been characterized in several reports describing their combined use.<sup>1,2,3,4,5,6,7,8</sup> This may relate at least in part to the combined antimicrobial actions of the agents, and even synergy against some pathogens.<sup>9,10</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated clindamycin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bernard A, Kermarrec G, Parize P, et al. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. <i>J Infect</i>. 2015;71(2):200-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25936632\">[PubMed 25936632]</a></p>\n<p>2. Curis E, Pestre V, Jullien V, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. <i>Infection</i>. 2015;43(4):473-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25837442\">[PubMed 25837442]</a></p>\n<p>3. Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. <i>Antimicrob Agents Chemother</i>. 2010;54(1):88-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19841148\">[PubMed 19841148]</a></p>\n<p>4. Join-Lambert O, Ribadeau-Dumas F, Jullien V, et al. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. <i>Eur J Dermatol</i>. 2014;24(1):94-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24445967\">[PubMed 24445967]</a></p>\n<p>5. Czekaj J, Dinh A, Moldovan A, et al. Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections. <i>Scand J Infect Dis</i>. 2011;43(11-12):962-967. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21916775\">[PubMed 21916775]</a></p>\n<p>6. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. <i>Dermatology</i>. 2009;219(2):143-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19590174\">[PubMed 19590174]</a></p>\n<p>7. Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. <i>Br J Dermatol</i>. 2006;154(5):977-978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16634904\">[PubMed 16634904]</a></p>\n<p>8. Bettoli V, Zauli S, Borghi A. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. <i>J Eur Acad Dermatol Venereol</i>. 2014;28(1):125-126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23451831\">[PubMed 23451831]</a></p>\n<p>9. Arditi M, Yogev R. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. <i>Antimicrob Agents Chemother</i>. 1989;33(2):245-247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2719468\">[PubMed 2719468]</a></p>\n<p>10. Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. <i>J Infect Dis</i>. 1981;144(4):365-371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6270215\">[PubMed 6270215]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10879":"<p><b>Title</b> Clindamycin (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving these combinations closely for reduced clindamycin clinical effects.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone<br><b>Exception</b> RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 34 patients with severe osteoarticular infections randomly assigned to receive clindamycin (600 mg orally 3 times daily) with either levofloxacin (500 mg orally daily) or the strong CYP3A4 inducer rifampin (600 mg orally twice daily) for 30 days, rifampin coadministration was associated with average decreases in maximum and minimum clindamycin serum concentrations of 66% and 83%, respectively.<sup>1</sup> Clinical cure rates at a mean of 23 months (n=24 patients) were similar between treatments. Consistent with these results, mean minimum clindamycin plasma concentrations were 70% lower in patients (n=6) receiving rifampin-containing regimens in a retrospective observational analysis of 61 patients hospitalized with osteoarticular infections,<sup>2</sup> and mean clindamycin concentrations were 40% lower in patients receiving concomitant rifampin (n=56) in a study of 70 patients receiving intravenous clindamycin infusion for treatment of osteoarticular infections.<sup>3</sup> Additionally, clindamycin maximum and minimum serum concentrations were lower by 82% and 92%, respectively, in a report of data from 10 patients receiving clindamycin with rifampin compared with historical control patients receiving clindamycin alone.<sup>4</sup><br><br>Despite the potential for a substantial pharmacokinetic interaction between rifampin and clindamycin, no clinically detrimental effects have been characterized in several reports describing their combined use.<sup>1,2,3,4,5,6,7,8</sup> This may relate at least in part to the combined antimicrobial actions of the agents, and even synergy against some pathogens.<sup>9,10</sup> No such therapeutic advantages are expected with most other clindamycin - strong CYP3A4 inducer combinations, and no data supporting safety and efficacy of such combinations are available.<br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated clindamycin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bernard A, Kermarrec G, Parize P, et al. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. <i>J Infect</i>. 2015;71(2):200-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25936632\">[PubMed 25936632]</a></p>\n<p>2. Curis E, Pestre V, Jullien V, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. <i>Infection</i>. 2015;43(4):473-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25837442\">[PubMed 25837442]</a></p>\n<p>3. Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. <i>Antimicrob Agents Chemother</i>. 2010;54(1):88-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19841148\">[PubMed 19841148]</a></p>\n<p>4. Join-Lambert O, Ribadeau-Dumas F, Jullien V, et al. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. <i>Eur J Dermatol</i>. 2014;24(1):94-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24445967\">[PubMed 24445967]</a></p>\n<p>5. Czekaj J, Dinh A, Moldovan A, et al. Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections. <i>Scand J Infect Dis</i>. 2011;43(11-12):962-967. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21916775\">[PubMed 21916775]</a></p>\n<p>6. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. <i>Dermatology</i>. 2009;219(2):143-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19590174\">[PubMed 19590174]</a></p>\n<p>7. Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. <i>Br J Dermatol</i>. 2006;154(5):977-978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16634904\">[PubMed 16634904]</a></p>\n<p>8. Bettoli V, Zauli S, Borghi A. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. <i>J Eur Acad Dermatol Venereol</i>. 2014;28(1):125-126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23451831\">[PubMed 23451831]</a></p>\n<p>9. Arditi M, Yogev R. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. <i>Antimicrob Agents Chemother</i>. 1989;33(2):245-247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2719468\">[PubMed 2719468]</a></p>\n<p>10. Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. <i>J Infect Dis</i>. 1981;144(4):365-371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6270215\">[PubMed 6270215]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10893":"<p><b>Title</b> Alcohol (Ethyl) / Dimethindene (Topical)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is mentioned only in dimethindene nasal product labeling. It is not mentioned in dimethindene topical gel product information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dimethindene (Topical) may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients should avoid alcohol consumption while taking dimethindene nasal products.</p> \n<p><b>Discussion</b> Dimethindene nasal product labeling states that dimethindene may cause drowsiness and should not be combined with alcoholic beverages.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vibrocil nasal drops, nasal gel, nasal spray, and microdoser (dimetindene maleate/phenylephrine base) [prescribing information]. Petach-Tikva, Israel: Promedico Ltd; November 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10894":"<p><b>Title</b> CNS Depressants / Dimethindene (Topical)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is mentioned only in dimethindene nasal product labeling. It is not mentioned in dimethindene topical gel product information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dimethindene (Topical) may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased somnolence or CNS depressant effects if dimethindene is combined with other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Dimethindene product labeling states that dimethindene may cause drowsiness and should be used with caution when combined with other CNS depressants.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vibrocil nasal drops, nasal gel, nasal spray, and microdoser (dimetindene maleate/phenylephrine base) [prescribing information]. Petach-Tikva, Israel: Promedico Ltd; November 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10895":"<p><b>Title</b> Oxomemazine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Oxomemazine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The oxomemazine patient leaflet states that administration of oxomemazine and antacids should be separated by at least 2 hours.<sup>1</sup> No data is available to describe a potential interaction between oxomemazine and antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10896":"<p><b>Title</b> CNS Depressants / Oxomemazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Oxomemazine may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of oxomemazine and CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The oxomemazine patient leaflet states that oxomemanzine should not be used in combination with other CNS depressants due to the risk of oversedation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10897":"<p><b>Title</b> Warfarin / Methotrexate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methotrexate may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of an increased warfarin response (ie, INR, signs and symptoms of bleeding) when used together with methotrexate.</p> \n<p><b>Discussion</b> Evidence regarding this specific interaction is limited to a report of 3 patient cases where patients receiving warfarin and combination chemotherapy regimens that included methotrexate experienced elevated prothrombin times and minor bleeding.<sup>1</sup> What role methotrexate played in these apparent interactions, if any, is unclear as all chemotherapy regimens included at least one other drug with more substantial evidence indicating an ability to increase the effects of warfarin. A combination of fluorouracil, cyclophosphamide, and methotrexate was used in two of the cases, and both fluorouracil and cyclophosphamide have been associated with increased warfarin effects, with the most substantial evidence supporting an interaction with fluorouracil. Similarly, the other case involved a patient receiving an eight-drug combination, including etoposide, prednisone, and cyclophosphamide, all of which have been associated with increased warfarin effects. Considering the lack of other evidence for a specific methotrexate-warfarin interaction and the presence of other data supporting interactions with other components of these chemotherapy regimens, it seems most likely that the observed interactions in these cases are due to other components of the chemotherapy regimens, even though some contributory role of methotrexate cannot be ruled-out entirely.<br><br>The mechanism of any methotrexate-warfarin interaction is unclear, and any interaction in this population may involve confounding factors such as age, the underlying malignancy, other concomitant medications, and other comorbidities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seifter EJ, Brooks BJ Jr, Urba WJ. Possible interactions between warfarin and antineoplastic drugs. <i>Cancer Treat Rep</i>. 1985;69(2):244-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3971397\">[PubMed 3971397]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10898":"<p><b>Title</b> Fosphenytoin-Phenytoin / Erlotinib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erlotinib may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of erlotinib with strong CYP3A4 inducers like phenytoin when possible. If such a combination cannot be avoided, the erlotinib prescribing information recommends increasing the erlotinib dose by 50 mg increments at 2 week intervals, as tolerated, to a maximum of 450 mg/day. Careful monitoring of phenytoin concentrations during and after erlotinib treatment, as well as monitoring for signs or symptoms of phenytoin toxicity is also recommended if the combination is used.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> According to one published case report, erlotinib concentrations were 79% to 92% lower during concomitant administration of the strong CYP3A4 inducer phenytoin.<sup>1</sup> The erlotinib AUC was reduced by an average of 67% to 81% with concomitant administration of rifampin (600 mg/day for 7 to 11 days), another strong CYP3A4 inducer, in two separate studies of healthy volunteers.<sup>2</sup> As a result of this apparent interaction, the erlotinib prescribing information recommends avoiding combined use with strong CYP3A4 inducers when possible, and when the combination must be used, increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<sup>3</sup><br><br>Erlotinib also appears to alter phenytoin concentrations as two case reports describe patients whose phenytoin concentrations increased approximately 3-fold or more following initiation of erlotinib (150 mg/day).<sup>1,4</sup> These increases were noted within 2 weeks in one case and after 7 months in the other case. Both patients also demonstrated signs or symptoms of phenytoin toxicity consistent with the increased phenytoin concentrations. Because of the reported effect of erlotinib on phenytoin, monitoring of phenytoin levels and careful observation for phenytoin toxicities such as nystagmus, diplopia, and ataxia appears warranted with any combined use.<br><br>The likely mechanism for the decrease in erlotinib concentrations is increased CYP3A-mediated metabolism of erlotinib by phenytoin, as erlotinib metabolism is primarily mediated by CYP3A4.<sup>1,2</sup> The mechanism by which erlotinib increases phenytoin concentrations is largely unknown, but the authors of this case suggested the possibility of erlotinib inhibition of phenytoin metabolism via CYP2C9 or CYP2C19, although there is no data to indicate erlotinib inhibits these enzymes.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ohgami M, Kaburagi T, Kurosawa A, Homma M. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer. <i>Lung Cancer</i>. 2016;101:9-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27794414\">[PubMed 27794414]</a></p>\n<p>2. Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2014;73(3):613-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24474302\">[PubMed 24474302]</a></p>\n<p>3. Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; April 2014.</p>\n<p>4. Grenader T, Gipps M, Shavit L, Gabizon A. Significant drug interaction: phenytoin toxicity due to erlotinib. <i>Lung Cancer</i>. 2007;57(3):404-406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17383767\">[PubMed 17383767]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10899":"<p><b>Title</b> Methoxyflurane / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If possible, avoid this drug combination.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> A retrospective analysis of 115 patients undergoing abdominal or thoracic operations suggests that renal failure is more likely in patients receiving both methoxyflurane and tetracycline.<sup>1</sup> Five of seven patients who received methoxyflurane and tetracycline had an elevated BUN or serum creatinine. None of the 108 patients who received methoxyflurane and other antibiotics had renal abnormalities. In addition, none of the 40 patients who received tetracycline and spinal anesthesia had an increase in BUN or serum creatinine. Several other cases of renal failure following methoxyflurane anesthesia in patients receiving tetracyclines have also been reported.<sup>2,3,4</sup> Although the present evidence for this interaction is only suggestive, avoid this drug combination if possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuzucu EY. Methoxyflurane, tetracycline, and renal failure. <i>JAMA</i>. 1970;211(7):1162-1164. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5466967\">[PubMed 5466967]</a></p>\n<p>2. Albers DD, Leverett CL, Sandin JH. Renal failure following prostatovesiculectomy related to methoxyflurane anesthesia and tetracycline--complicated by Candida infection. <i>J Urol</i>. 1971;106(3):348-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5097184\">[PubMed 5097184]</a></p>\n<p>3. Proctor EA, Barton FL. Polyuric acute renal failure after methoxyflurane and tetracycline. <i>Br Med J</i>. 1971;4(5788):661-662. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5134563\">[PubMed 5134563]</a></p>\n<p>4. Stoelting RK, Gibbs PS. Effect of tetracycline therapy on renal function after methoxyflurane anesthesia. <i>Anesth Analg</i>. 1973;52(3):431-436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4735998\">[PubMed 4735998]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}